Donato Tramuto

RFK Human Rights Board Member, Business Leader, Author

Donato J. Tramuto, is the former CEO of Tivity Health® , Inc., and is widely recognized for his commitment to social change and transformational leadership in healthcare innovation that led the New York Times to deem him “a global health activist.”

Tramuto is also the founder and chair of The Tramuto Foundation which advances young people’s rights to education and healthcare access and combats human right violations. He launched the foundation in memory of his two friends and their 3 year old son who lost their lives on 9/11 when United Flight 175 crashed into the South Tower. Tramuto was scheduled to be on that flight, however and due to a toothache, he never boarded the plane. Since the launch of the foundation, over 100 young adults have received a Tramuto Foundation Scholarship to pursue their dream of a College Education and many organizations have received financial and partnership support helping them deliver on their promise to make the world a more equitable place.

His three-decade commitment to social change and innovation has earned numerous awards, including the prestigious Robert F. Kennedy Ripple of Hope (2014) and the RFK Embracing His Legacy Awards (2016). Tramuto currently serves as a member of the board of Robert F. Kennedy Human Rights and is chairman of its Leadership Council where his foundation has committed to funding a three-year, $1 million grant to address workplace bullying, leading a national initiative to address workplace dignity and inclusion in the U.S. and Europe.

Tramuto is a passionate champion of cutting-edge approaches to healthcare access, drug safety, and addressing the social determinants of health (SDOH), defined by the World Health Organization as the conditions in which people are born, grow, live, work and age. Under his tenure as CEO of Tivity Health and following his execution of a successful turnaround, he transformed the business business model to center around partnering progressively, profitably and collaboratively with consumers, payers, healthcare practitioners and employers in cutting-edge approaches to SDOH conditions including nutrition, fitness and social connection, that improve health outcomes and reduce medical costs.

Before joining Tivity Health, Tramuto’s record of bringing together social commitment with healthcare innovation included his founding of Physicians Interactive Holdings (Aptus Health sold to WebMD in 2019), a global provider of insight-driven digital engagement solutions for healthcare professionals and consumers. Reflecting a conviction that universal healthcare is a basic human right for all people, he launched Health eVillages in 2011, a non-profit organization providing state-of-the-art mobile health technology in the most challenging clinical environments and working to broaden healthcare access.

Tramuto is a member of the Brown University Healthcare Leadership Board, as well as a member of the Advisory Board of Boston University School of Public Health. He is a member of the Board of Directors of the Livongo Health Foundation, Sharecare, Inc., Cherish Health Inc., Robert F. Kennedy Human Rights, Robert F Kennedy Human Rights Europe, Health eVillages, and the Gryphon Investment Executive Advisory Board. In June, he joined Promerica Health as Executive Chairman in Residence and in August, he was appointed Honorary Scholar in Residence at St. Joseph’s College in Maine. He is the mastermind behind a groundbreaking 360° public service campaign and annual summit addressing challenges unique to older adults, including the too-often overlooked issues of isolation and loneliness.

A proponent of lifeling learning, Tramuto holds honorary doctorates from the University of Massachusetts at Lowell, Thomas Jefferson University, Lasell College and Saint Joseph’s College, and is the author of Life’s Bulldozer Moments: How Adversity Leads to Success in Life and Business. Tramuto’s 2nd book, The Double Bottom Line, How Compassionate Leaders Captivate Hearts and Deliver Results, will be released on February 1st, 2022.

Read the full profile on The Marque